Adrestia Therapeutics is founded in 2018, operates from its headquarter in Babraham Research Campus Moneta Building 280 GB,England,Cambridge,CB22 3AT. The company operates in the Hospitals & Healthcare, Medical Practices sector.
Adrestia Therapeutics specializes in Synthetic lethality, Genetic network decoding, Treatment of genetic diseases, Platform development for genetic therapies, and offers services including Synthetic rescue approach, World-first validated targets, and Multi-target discovery alliance.